| 1 | to treat cancer for | | | | | | | 2 | 0.79% |
| 2 | the forwardlooking statements involve | | | | | | | 1 | 0.40% |
| 3 | own proprietary therapeutic products | | | | | | | 1 | 0.40% |
| 4 | proprietary therapeutic products to | | | | | | | 1 | 0.40% |
| 5 | therapeutic products to treat | | | | | | | 1 | 0.40% |
| 6 | products to treat cancer | | | | | | | 1 | 0.40% |
| 7 | investors disclaimer this website | | | | | | | 1 | 0.40% |
| 8 | disclaimer this website contains | | | | | | | 1 | 0.40% |
| 9 | this website contains historical | | | | | | | 1 | 0.40% |
| 10 | website contains historical and | | | | | | | 1 | 0.40% |
| 11 | forwardlooking statements the forwardlooking | | | | | | | 1 | 0.40% |
| 12 | statements the forwardlooking statements | | | | | | | 1 | 0.40% |
| 13 | skip to content advanced | | | | | | | 1 | 0.40% |
| 14 | and our own proprietary | | | | | | | 1 | 0.40% |
| 15 | forwardlooking statements involve risks | | | | | | | 1 | 0.40% |
| 16 | and uncertainties forward looking | | | | | | | 1 | 0.40% |
| 17 | uncertainties forward looking statements | | | | | | | 1 | 0.40% |
| 18 | forward looking statements appearing | | | | | | | 1 | 0.40% |
| 19 | looking statements appearing on | | | | | | | 1 | 0.40% |
| 20 | statements appearing on this | | | | | | | 1 | 0.40% |
| 21 | appearing on this website | | | | | | | 1 | 0.40% |
| 22 | in this presentation represent | | | | | | | 1 | 0.40% |
| 23 | this presentation represent managements | | | | | | | 1 | 0.40% |
| 24 | presentation represent managements current | | | | | | | 1 | 0.40% |
| 25 | our own proprietary therapeutic | | | | | | | 1 | 0.40% |
| 26 | be licensed by others | | | | | | | 1 | 0.40% |
| 27 | managements current estimates at | | | | | | | 1 | 0.40% |
| 28 | superior targeted therapeutics to | | | | | | | 1 | 0.40% |
| 29 | superior targeted cancer therapeutics | | | | | | | 1 | 0.40% |
| 30 | targeted cancer therapeutics our | | | | | | | 1 | 0.40% |
| 31 | company partnership opportunities leverage | | | | | | | 1 | 0.40% |
| 32 | partnership opportunities leverage our | | | | | | | 1 | 0.40% |
| 33 | opportunities leverage our novel | | | | | | | 1 | 0.40% |
| 34 | leverage our novel chemistries | | | | | | | 1 | 0.40% |
| 35 | our novel chemistries to | | | | | | | 1 | 0.40% |
| 36 | create your superior targeted | | | | | | | 1 | 0.40% |
| 37 | your superior targeted therapeutics | | | | | | | 1 | 0.40% |
| 38 | partners investment opportunities we | | | | | | | 1 | 0.40% |
| 39 | to be licensed by | | | | | | | 1 | 0.40% |
| 40 | to content advanced proteome | | | | | | | 1 | 0.40% |